{"date":"2025-11-27","count":18,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-1795-2025-11-27-2230-98v35q","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"22:30:10","subject":"代子公司Lotus US Financing S.a.r.l.公告現金增資","clause":"第11款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-11-27 22:30，「代子公司Lotus US Financing S.a.r.l.公告現金增資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-11-27-2228-1vwqd6r","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"22:28:54","subject":"代盧森堡子公司Lotus US Financing S.à.r.l.公告實物增資取得有價證券","clause":"第20款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-11-27 22:28，「代盧森堡子公司Lotus US Financing S.à.r.l.公告實物增資取得有價證券」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-11-27-2228-1k1d4n2","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"22:28:35","subject":"公告本公司處分New Alvogen Group Holding, Inc.特別股股權","clause":"第20款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-11-27 22:28，「公告本公司處分New Alvogen Group Holding, Inc.特別股股權」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2025-11-27-2228-qskcem","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"22:28:19","subject":"公告董事會決議通過增資盧森堡子公司 Lotus US Financing S.à.r.l.","clause":"第20款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：美時（1795），2025-11-27 22:28，「公告董事會決議通過增資盧森堡子公司 Lotus US Financing S.à.r.l.」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6580-2025-11-27-1917-19g33dx","company_id":"6580","company":"台睿","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"19:17:23","subject":"公告本公司抗癌口服研發中新藥 CVM-1118用於治療中期肝癌，獲中國國家藥品監督管理局核准執行第二期臨床試驗。","clause":"第44款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：台睿（6580），2025-11-27 19:17，「公告本公司抗癌口服研發中新藥 CVM-1118用於治療中期肝癌，獲中國國家藥品監督管理局核准執行第二期臨床試驗。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2025-11-27-1910-1ka8y5r","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-11-27","time":"19:10:44","subject":"本公司有價證券近期股價量異常，故公告相關訊息，以利投資人區別暸解","clause":"第53款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-11-27 19:10，「本公司有價證券近期股價量異常，故公告相關訊息，以利投資人區別暸解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6661-2025-11-27-1705-vpt0hc","company_id":"6661","company":"威健生技","market":"上櫃","industry":"生技醫療","date":"2025-11-27","time":"17:05:17","subject":"公告本公司召開線上法人說明會","clause":"第12款","fact_date":"2025-11-28","cite_as":"公開資訊觀測站重大訊息：威健生技（6661），2025-11-27 17:05，「公告本公司召開線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-11-27-1636-oop30m","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"16:36:58","subject":"本公司TAH3311抗血栓口溶膜505(b)(2)新劑型新藥藥證申請接獲美國食品藥物管理局(FDA)資料不完全通知(補充說明)","clause":"第44款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-11-27 16:36，「本公司TAH3311抗血栓口溶膜505(b)(2)新劑型新藥藥證申請接獲美國食品藥物管理局(FDA)資料不完全通知(補充」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6467-2025-11-27-1611-1o5s7l3","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"16:11:48","subject":"公告本公司TAH3311抗血栓口溶膜上市許可申請(MAA)獲歐洲藥品管理局(EMA)受理正式進入審理流程","clause":"第44款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2025-11-27 16:11，「公告本公司TAH3311抗血栓口溶膜上市許可申請(MAA)獲歐洲藥品管理局(EMA)受理正式進入審理流程」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7595-2025-11-27-1549-1j3f65v","company_id":"7595","company":"世基生醫","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"15:49:36","subject":"公告本公司總經理變動事宜","clause":"第6款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：世基生醫（7595），2025-11-27 15:49，「公告本公司總經理變動事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7595-2025-11-27-1548-ri35y","company_id":"7595","company":"世基生醫","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"15:48:56","subject":"公告本公司董事長變動事宜","clause":"第6款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：世基生醫（7595），2025-11-27 15:48，「公告本公司董事長變動事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-11-27-1535-1pzjlpi","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-11-27","time":"15:35:14","subject":"公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形","clause":"第44款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-11-27 15:35，「公告本公司預估未來三個月現金收支情形及銀行可使用融資額度情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-11-27-1518-1b4kvx7","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-11-27","time":"15:18:49","subject":"公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」韓國專利核准通知書。","clause":"第53款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-11-27 15:18，「公告本公司收到「NALTREXONE INJECTABLE SUSTAINEDRELEASE FORMULATION」韓」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7799-2025-11-27-1506-6z3e6a","company_id":"7799","company":"禾榮科","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"15:06:47","subject":"本公司與歐洲尖端技術的系統整合發展領導企業Cosylab d.d.簽署互為代理的合作意向書","clause":"第10款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：禾榮科（7799），2025-11-27 15:06，「本公司與歐洲尖端技術的系統整合發展領導企業Cosylab d.d.簽署互為代理的合作意向書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-11-27-1425-j4bt4x","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"14:25:17","subject":"公告本公司國內第二次無擔保轉換公司債委託代收價款及存儲專戶行庫","clause":"第51款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-11-27 14:25，「公告本公司國內第二次無擔保轉換公司債委託代收價款及存儲專戶行庫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-11-27-1424-1izwmma","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"14:24:18","subject":"公告本公司114年現金增資認股基準日等相關事宜","clause":"第11款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-11-27 14:24，「公告本公司114年現金增資認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4142-2025-11-27-1415-1cyn967","company_id":"4142","company":"國光生","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"14:15:01","subject":"公告本公司財務主管及會計主管異動","clause":"第8款","fact_date":"2025-11-27","cite_as":"公開資訊觀測站重大訊息：國光生（4142），2025-11-27 14:15，「公告本公司財務主管及會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6491-2025-11-27-1050-1ybv272","company_id":"6491","company":"晶碩","market":"上市","industry":"生技醫療","date":"2025-11-27","time":"10:50:34","subject":"澄清114年11月26日新聞媒體報導","clause":"第51款","fact_date":"2025-11-26","cite_as":"公開資訊觀測站重大訊息：晶碩（6491），2025-11-27 10:50，「澄清114年11月26日新聞媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}